Last reviewed · How we verify
Methotrexate, Leucovorin and BMS-986142 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Methotrexate, Leucovorin and BMS-986142 (Methotrexate, Leucovorin and BMS-986142) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Methotrexate, Leucovorin and BMS-986142 TARGET | Methotrexate, Leucovorin and BMS-986142 | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Methotrexate, Leucovorin and BMS-986142 CI watch — RSS
- Methotrexate, Leucovorin and BMS-986142 CI watch — Atom
- Methotrexate, Leucovorin and BMS-986142 CI watch — JSON
- Methotrexate, Leucovorin and BMS-986142 alone — RSS
Cite this brief
Drug Landscape (2026). Methotrexate, Leucovorin and BMS-986142 — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-leucovorin-and-bms-986142. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab